Tyra Biosciences Inc Market Cap ($1.13 Billion)
Market Cap & Net Worth: Tyra Biosciences Inc (TYRA)
Tyra Biosciences Inc market cap. Tyra Biosciences Inc (NASDAQ:TYRA) has a market capitalization of $1.13 Billion ($1.13 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8056 globally and #2408 in its home market, demonstrating a 0.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tyra Biosciences Inc's stock price $21.07 by its total outstanding shares 53867115 (53.87 Million). Also see Tyra Biosciences Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Tyra Biosciences Inc Market Cap History (2021–2026)
Tyra Biosciences Inc market cap history from 2021 to 2026. Data shows change from $757.91 Million to $1.13 Billion (-4.02% CAGR). Check current stock price of Tyra Biosciences Inc for real-time trading data and today's change.
Index Memberships
Tyra Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.04% | #233 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #888 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.06% | #135 of 263 |
Weight: Tyra Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tyra Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tyra Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Tyra Biosciences Inc (TYRA) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TYRA by Market Capitalization
Companies near Tyra Biosciences Inc in the global market cap rankings as of November 1, 2026. Also see TYRA current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Tyra Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Tyra Biosciences Inc (2021–2026)
Market capitalization of Tyra Biosciences Inc from 2021 to today. Between 2021 and today, Tyra Biosciences Inc's market cap moved from $757.91 Million to $ 1.13 Billion, with a yearly change of -4.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.13 Billion | -19.86% |
| 2025 | $1.42 Billion | +89.14% |
| 2024 | $748.75 Million | +0.36% |
| 2023 | $746.06 Million | +82.24% |
| 2022 | $409.39 Million | -45.98% |
| 2021 | $757.91 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Tyra Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more